Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms
Authors:
Open Access
- 9 July 2026
- journal article
- Published by Elsevier in Cancer Cell
- Vol. 44 (8) , 1639-1652.e6
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- Syndax Pharmaceuticals
- American Lebanese Syrian Associated Charities
- Leukemia and Lymphoma Society
This publication has 36 references indexed in Scilit:
- Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic SyndromesAmerican Journal of Hematology, 2025
- Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- The Role of Megakaryocytes in MyelofibrosisHematology/Oncology Clinics of North America, 2021
- Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific TargetsMolecular Cell, 2020
- Management of myelofibrosis after ruxolitinib failureAnnals of Hematology, 2020
- A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged LeukemiaCancer Cell, 2019
- Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKLCell, 2012
- Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemiaNature Chemical Biology, 2012
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organsMechanisms of Development, 2003